StoxDr. Lal Path Labs vs Rubicon Research: share price & financials comparison
NSE: LALPATHLAB vs RUBICON · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Dr. Lal Path Labs vs Rubicon Research at a glance
Dr. Lal Path Labs (LALPATHLAB) has a market capitalisation of ₹33,443 Cr, against ₹27,763 Cr for Rubicon Research (RUBICON). Over the past year Rubicon Research has returned +157.0%, compared with +26.4% for Dr. Lal Path Labs. On valuation, Dr. Lal Path Labs trades at a lower P/E of 57.3 versus 85.5. Rubicon Research earns a higher return on equity (22.9% vs 21.3%). Dr. Lal Path Labs comes out ahead on size, valuation and profitability. Rubicon Research comes out ahead on growth, momentum and technicals. Across the scored metrics below, Dr. Lal Path Labs leads on 7 and Rubicon Research on 6. On StoxGud's 10-point checklist, Dr. Lal Path Labs scores 9/10 and Rubicon Research scores 8/10.
| Metric | Dr. Lal Path Labs | Rubicon Research |
|---|---|---|
| Size | ||
| Market cap | ₹33,443 Cr | ₹27,763 Cr |
| Revenue (latest FY) | ₹2,763 Cr | ₹1,754 Cr |
| Net profit (latest FY) | ₹505 Cr | ₹247 Cr |
| Valuation | ||
| P/E | 57.3 | 85.5 |
| P/B | 12.19 | 19.60 |
| Dividend yield | 0.67% | 0.00% |
| Profitability | ||
| Return on equity | 21.3% | 22.9% |
| Net profit margin | 19.2% | 15.5% |
| Operating margin | 29.5% | 23.8% |
| Growth | ||
| Revenue growth (YoY) | +19.6% | +39.9% |
| Net profit growth (YoY) | +27.6% | +68.0% |
| Revenue CAGR (multi-year) | +11.8% | — |
| Financial health | ||
| Debt to equity | 0.00 | 0.28 |
| Momentum | ||
| 1-month return | +4.3% | +10.1% |
| 1-year return | +26.4% | +157.0% |
| 3-year CAGR | +15.0% | — |
| 5-year CAGR | +1.7% | — |
| 10-year CAGR | +13.7% | — |
| Distance from 52W high | -1.8% | -9.9% |
| Technicals | ||
| RSI (14) | 68 | 71 |
| Price vs 200-day avg | +19.8% | +34.3% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Dr. Lal Path Labs | Rubicon Research |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 9/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Dr. Lal Path Labs or Rubicon Research?
Dr. Lal Path Labs has a market cap of ₹33,443 Cr and Rubicon Research has a market cap of ₹27,763 Cr as of 13 Nov 2026.
Which has a lower P/E, Dr. Lal Path Labs or Rubicon Research?
Dr. Lal Path Labs has the lower P/E: Dr. Lal Path Labs trades at 57.3 and Rubicon Research at 85.5.
Which gave better returns in the last year, Dr. Lal Path Labs or Rubicon Research?
Rubicon Research did better: Dr. Lal Path Labs returned +26.4% and Rubicon Research returned +157.0% over one year.
What is the difference between Dr. Lal Path Labs and Rubicon Research?
Both are NSE-listed companies in Healthcare. Dr. Lal Path Labs is about 1.2 times the size of Rubicon Research by market cap. In the latest financial year Dr. Lal Path Labs reported revenue of ₹2,763 Cr and Rubicon Research ₹1,754 Cr. Operating margin is 29.5% for Dr. Lal Path Labs and 23.8% for Rubicon Research. Debt to equity is 0.00 for Dr. Lal Path Labs and 0.28 for Rubicon Research.
Which is better, Dr. Lal Path Labs or Rubicon Research?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Dr. Lal Path Labs leads on 7 and Rubicon Research on 6. Dr. Lal Path Labs is ahead on size, valuation and profitability. Rubicon Research is ahead on growth, momentum and technicals. On StoxGud's rules-based checklist Dr. Lal Path Labs scores 9/10 and Rubicon Research scores 8/10. This is information, not advice: consult a SEBI-registered adviser before investing.